NPCR > Publikationer > 2015

2015

  1. RE: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma, Damber JE. Eur Urol. 2015 Dec;68(6):1102. Sammanfattning, Fulltext
  2. Stattin K, Sandin F, Bratt O, Lambe M, The risk of distant metastases and cancer-specific survival in men with serum prostate-specific antigen values above 100 ng/ml, J Urol, 2015 Dec;194(6):1594-600. Sammanfattning
  3. Lindhagen L, Van Hemelrijck M, Robinson D, Stattin P, Garmo H. How to model temporal changes in comorbidity for cancer patients using prospective cohort data, BMC Med Inform Decis Mak. 2015 Nov 18;15:96. Sammanfattning, Fulltext
  4. Melvin JC, Garmo H, Daniel R, Shanmugalingam T, Stattin P, Häggström C, Rudman S, Holmberg L, Van Hemelrick M, An investigation into the relationship between Statins and Cancer using population-based data, BJU Int, 2015 Nov;116(5):681-3. Sammanfattning
  5. Stattin P, Robinson D, Lambe M, Re: Giorgio Gandaglia, Freddie Bray, Matthew R. Cooperberg, et al. Prostate Cancer Registries: Current Status and Future Directions, Eur Urol, 2015 Nov;68(5):e110. Sammanfattning, Fulltext
  6. Loeb S, Schlomm T, Stattin P, Associations Do Not Equal Causation: Clinical Relevance of Statistical Associations of Phosphodiesterase Type 5 Inhibitors with Prostate Cancer Progression and Melanoma, Eur Urol, 2015 Nov;68(5):754-5. Sammanfattning
  7. Robinson D, Garmo H, Stattin P, Michaëlsson K. Risk of Fractures and Falls during and after 5-α Reductase Inhibitor Use: A Nationwide Cohort Study, PLoS One, 2015 Oct 15;10(10):e0140598. Sammanfattning
  8. Grott A, Bottai M, Adami HO, Adams SA, Akre O, Blair SN, Mariosa D, Nyrén O, Ye W, Stattin P, Bellocco R, Lagerros YT, Physical activity and body mass index as predictors of prostate cancer risk, World J Urol, 2015 Oct;33(10):1495-502. Sammanfattning
  9. Robinson D, Garmo H, Holmberg L, Stattin P, 5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer, Cancer Causes Control, 2015 Sep;26(9):1289-97. Sammanfattning, fulltext
  10. Markt SC, Grotta A, Nyren O, Adami HO, Mucci LA, Valdimarsdottir UA, Stattin P, Bellocco R, Lagerros YT, Insufficient Sleep and Risk of Prostate Cancer in a Large Swedish Cohort, Sleep, 2015 Sep 1;38(9):1405-10. Sammanfattning
  11. Bratt O, Folkvaljon Y, Loeb S, Klotz L, Egevad L, Stattin P, Upper Limit of Cancer Extent on Biopsy Defining Very Low Risk Prostate Cancer, BJU Int, 2015 Aug;116(2):213-9. Sammanfattning
  12. Stattin P, Vickers AJ, Sjoberg DD, Johansson R, Granfors T, Johansson M, Petterson K, Scardino PT, Hallmans G, Lilja H, Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study, Eur Urol, 2015 Aug;68(2):207-13. Fulltext
  13. Stacy Loeb, Yasin Folkvaljon, Mats Lambe, David Robinson, Hans Garmo, Christian Ingvar, Pӓr Stattin, Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma, JAMA. 2015 Jun 23-30;313(24):2449-55. Sammanfattning
  14. Bratt O, Folkvaljon Y, Hjälm Eriksson M, Akre O, Carlsson S, Drevin L, Franck Lissbrant I, Makarov D, Loeb S, Stattin P, Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer, Eur Urol. 2015 Jul;68(1):53-8. Sammanfattning, fulltext
  15. O’Farrel S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M, Risk and Timing of Cardiovascular Disease After Androgen-Deprivation Therapy in Men With Prostate Cancer, J Clin Oncol, 2015 Apr 10;33(11):1243-51. Sammanfattning
  16. Danneman D, Drevin L, Robinson D, Stattin P, Egevad L. Gleason Inflation 1998-2011. A Registry Study of 97 168 Men. BJU Int, 2015 Feb;115(2):248-55 Sammanfattning
  17. Loeb S, Folkvaljon Y, Makarov DV, Bratt O, Bill-Axelson A, Stattin P, Five-year Nationwide Follow-up Study of Active Surveillance for Prostate Cancer, Eur Urol, 2015 Feb;67(2):233-8. Sammanfattning
  18. Tomic K, Berglund A, Robinson D, Hjälm-Eriksson M, Carlsson S, Lambe M, Stattin P. Capture rate and representativity of The National Prostate Cancer Register of Sweden, Acta Oncol, 2015 Feb;54(2):158-63 Sammanfattning
  19. Bonn, SE, Sjölander A, Lagerros YT, Wiklund F, Stattin P, Holmberg E, Grönberg H, Bälter K, Physical Activity and Survival among Men Diagnosed with Prostate Cancer, Cancer Epidemiol Biomarkers Prev 2015 Jan;24(1):57-64. Sammanfattning
  20. Tomic K, Sandin F, Wigertz A, Robinson D, Lambe M, Stattin P, Evaluation of data quality in the National Prostate Cancer Register of Sweden, Eur J Cancer, 2015 Jan;51(1):101-11. Sammanfattning. Fullständig text